SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (546)4/25/2000 9:38:00 AM
From: GeoDude  Read Replies (1) | Respond to of 666
 
Coulter Pharmaceutical Reacquires Rights to Bexxar Outside of the U.S. from SmithKline Beecham

Looks to me that SB does not see big potential in this drug. Not the elephant that big pharma needs. Decided to pass it on to a partner with lower overheads (CLTR). Unless SB is wrong, not good news for CLTR. Of course SB could be wrong ... Have they been wrong before?

LIA